Bank of America
APGE

Bank of America’s Apogee Therapeutics APGE Stock Holding History

Bank of America’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149M Buy
1,126,139
+225,268
+25% +$20.3M 0.01% 933
2026
Q1 		$75.8M Buy
900,871
+107,176
+14% +$7.78M 0.01% 1319
2025
Q4 		$59.9M Buy
793,695
+399,783
+101% +$25.2M ﹤0.01% 1431
2025
Q3 		$15.7M Sell
393,912
-115,075
-23% -$4.39M ﹤0.01% 2845
2025
Q2 		$22.1M Buy
508,987
+83,107
+20% +$3.16M ﹤0.01% 2455
2025
Q1 		$15.9M Buy
425,880
+320,340
+304% +$12.4M ﹤0.01% 2694
2024
Q4 		$4.78M Sell
105,540
-193,932
-65% -$9.89M ﹤0.01% 3635
2024
Q3 		$17.6M Sell
299,472
-50,084
-14% -$2.4M ﹤0.01% 2526
2024
Q2 		$13.8M Sell
349,556
-47,222
-12% -$2.29M ﹤0.01% 2620
2024
Q1 		$26.4M Sell
396,778
-92,431
-19% -$4.04M ﹤0.01% 2010
2023
Q4 		$13.7M Buy
489,209
+468,639
+2,278% +$9.39M ﹤0.01% 2542
2023
Q3 		$438K Buy
+20,570
New +$453K ﹤0.01% 5400

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Bank of America's APGE Position: Q2 2026 in Review

Bank of America increased its Apogee Therapeutics (APGE) stake by 25% in Q2 2026, buying an estimated $20.3M and bringing the position to 1,126,139 shares worth $149M. The position accounts for 0.01% of the portfolio, ranked #933.

Bank of America first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Bank of America held 1,126,139 shares of Apogee Therapeutics worth $149M as of Q2 2026.
  • Bank of America bought 225,268 Apogee Therapeutics shares in Q2 2026, an estimated $20.3M.
  • Apogee Therapeutics made up 0.01% of Bank of America's portfolio in Q2 2026, its #933 holding.
  • Bank of America first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.